3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
181
Colorectal Neoplasms
144
Stomach Neoplasms
90
Rectal Neoplasms
90
Pancreatic Neoplasms
74
Neoplasm Metastasis
60
Neoplasms
48
Colonic Neoplasms
40
Esophageal Neoplasms
31
Gallbladder Neoplasms
18
Biliary Tract Neoplasms
17
Bile Duct Neoplasms
17
Carcinoma, Hepatocellular
15
Triple Negative Breast Neoplasms
13
Cholangiocarcinoma
12
Adenocarcinoma
12
Unspecified Adult Solid Tumor, Protocol Specific
11
Parkinson Disease 4, Autosomal Dominant Lewy Body
11
Liver Neoplasms
10
Breast Neoplasms, Male
10
Adenocarcinoma Of Esophagus
10
Squamous Cell Carcinoma of Head and Neck
9
Head and Neck Neoplasms
9
Gastrointestinal Neoplasms
9
Carcinoma, Renal Cell
8
Carcinoma, Non-Small-Cell Lung
8
Brain Neoplasms
7
Prostatic Neoplasms
6
Ovarian Neoplasms
6
Uterine Cervical Neoplasms
5
Interventions
padeliporfin
4
Nivolumab
4
Gemcitabine
4
Cyclophosphamide
4
130-nm albumin-bound paclitaxel
4
napabucasin
3
Pemetrexed
3
Fluorouracil
3
Albumin-Bound Paclitaxel
3
ficlatuzumab
2
Trastuzumab
2
Trabectedin
2
Paclitaxel
2
Leucovorin
2
Irinotecan
2
Bevacizumab
2
sotorasib
1
selinexor
1
ribociclib
1
relatlimab
1
pralsetinib
1
pembrolizumab
1
pamiparib
1
osimertinib
1
nintedanib
1
ipatasertib
1
guadecitabine
1
glutathione pegylated liposomal doxorubicin
1
exemestane
1
entinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Neoplasms by Site
×
Capecitabine
×
Clear all
NCT04080843
2022-07-13
ALTER-C-002
Zhejiang University
Phase 2
Completed
30 enrolled